Merck picks circular path to RNA and commits $250M to biotech startup Orna

Merck aims to bolster its genetic medicines pipeline through a new research alliance with Orna Therapeutics, a startup whose technology forms RNA into a circle shape that brings several advantages for new therapies and vaccines. In addition to starting the partnership, the pharmaceutical giant also invested in Orna’s $221 million Series B financing round.

Leave a Comment

Your email address will not be published.